Parallel Advisors’s Epizyme, Inc EPZM Stock Holding History

Parallel Advisors’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-134	Closed	-$1K	–	3378
2021 Q2	$1K	Hold	134	–	–	﹤0.01%	2895
2021 Q1	$1K	Buy	+134	New	+$1.39K	﹤0.01%	2747

Other funds holding EPZM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

KXA

KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Parallel Advisors's EPZM Position: Q3 2021 in Review

Parallel Advisors sold out of Epizyme, Inc (EPZM) in Q3 2021, closing a stake of 134 shares — an estimated $1K sold.

Parallel Advisors first reported a position in EPZM in Q1 2021 and held it in 2 quarters. The position peaked at $1K in Q2 2021. 116 funds tracked by Wall St. Rank hold EPZM as of Q3 2021.

Parallel Advisors reported no remaining Epizyme, Inc position as of Q3 2021 after selling out during the quarter.
Parallel Advisors sold 134 Epizyme, Inc shares in Q3 2021, an estimated $1K.
Parallel Advisors first reported a position in Epizyme, Inc in Q1 2021 and held it in 2 quarters.
Parallel Advisors's Epizyme, Inc position peaked at $1K in Q2 2021.
116 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2021.

Based on Parallel Advisors's 13F filing for Q3 2021, filed 22 Oct 2021.